Joel Young, MD
Psychiatry · Rochester Hills, MINPI 1356325468
Payments from drug & device makers
What this record shows
The money is spread across several categories — grants (48.5%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. 27 manufacturers reported payments, led by Tris Pharma Inc at 51.7% of the total. 2025 is the largest year on record at $612,439, 3.9 times the $155,179 reported in 2019. Among psychiatry clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 800 payments — averaging $1394.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tris Pharma Inc$577K
- Supernus Pharmaceuticals, Inc.$142K
- Ironshore Pharmaceuticals Inc.$111K
- Johnson & Johnson$60K
- Corium, LLC$38K
- Noven Pharmaceuticals, Inc.$33K
- plus $154K from 21 others
Across 137 payments — averaging $13,752 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Tris Pharma Inc$687K
- Janssen Research & Development, LLC$371K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$362K
- Jazz Pharmaceuticals Inc.$286K
- Arbor Pharmaceuticals, Inc.$48K
- Sunovion Pharmaceuticals Inc.$39K
- plus $91K from 8 others
What the payments were for
- Consulting fees$85,0408%
- Speaking & faculty fees$425,43238%
- Grants$540,78148%
- Travel & lodging$48,3954%
- Food & beverage$15,9371%
- Education$300%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Tris Pharma Inc | 38 | $576,718 |
| Supernus Pharmaceuticals, Inc. | 141 | $142,224 |
| Ironshore Pharmaceuticals Inc. | 199 | $111,071 |
| Johnson & Johnson | 97 | $60,221 |
| Corium, LLC | 41 | $38,090 |
| Noven Pharmaceuticals, Inc. | 22 | $33,455 |
| Takeda Pharmaceuticals U.S.A., Inc. | 37 | $30,447 |
| Otsuka America Pharmaceutical, Inc. | 41 | $29,198 |
| Axsome Therapeutics, Inc. | 26 | $27,449 |
| Sunovion Pharmaceuticals Inc. | 35 | $15,257 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 18 | $13,459 |
| Adlon Therapeutics L.p. | 13 | $11,882 |
| Alkermes, Inc. | 17 | $11,587 |
| Collegium Pharmaceutical, Inc. | 5 | $5,735 |
| Shire North American Group Inc | 9 | $4,515 |
| Noven Therapeutics, LLC | 4 | $3,425 |
| Lundbeck LLC | 24 | $345 |
| AbbVie(2 entities) | 21 | $222 |
| Neurocrine Biosciences, Inc. | 1 | $128 |
| OWP Pharmaceuticals, Inc. | 3 | $39 |
| Jazz Pharmaceuticals Inc. | 2 | $34 |
| Teva Pharmaceuticals USA, Inc. | 1 | $26 |
| Vanda Pharmaceuticals Inc. | 1 | $24 |
| Neos Therapeutics, LP | 1 | $23 |
| Bausch Health US, LLC | 1 | $16 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
| Vertical Pharmaceuticals, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Dyanavel XR$576,226
- QELBREE$105,845
- Jornay PM 20mg capsules (Bottle of 100)$71,954
- SPRAVATO$59,242
- JORNAY PM$41,509
- Azstarys$37,313
- LYBALVI$36,303
- Quillivant$35,445
- Quillichew ER$35,445
- Xelstrym$32,508
- REXULTI$28,898
- Auvelity$26,828
- VYVANSE$20,889
- CAPLYTA$13,172
- ADHANSIA XR$11,792
- LATUDA$9,108
- DASOTRALINE$5,562
- TRINTELLIX$3,316
- INGREZZA$128
How this compares
$1,115,615 in reported general payments places this provider in the 95th percentile of 1,166 psychiatry providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SpravatoEsketamine Hcl | 103 | $129,584 |
| AuvelityDextromethorphan Hbr/Bupropion | 27 | $40,688 |
| RexultiBrexpiprazole | 11 | $16,278 |
| VyvanseLisdexamfetamine Dimesylate | 38 | $15,359 |
| Dyanavel XrAmphetamine | 15 | $6,214 |
| Lisdexamfetamine Dimesylate | 19 | $4,961 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 47 | $2,039 |
| Methylphenidate ErMethylphenidate Hcl | 30 | $1,739 |
| Bupropion XlBupropion Hcl | 42 | $689 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 43 | $636 |
| Duloxetine Hcl | 30 | $517 |
| Sertraline Hcl | 27 | $491 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 27 | $447 |
| Olanzapine | 11 | $403 |
| Methylphenidate Hcl | 23 | $365 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonSpravato | $60,221 | $129,584103 claims |
| Axsome Therapeutics, Inc.Auvelity | $27,449 | $40,68827 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $29,198 | $16,27811 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $30,447 | $15,35938 claims |
| Tris Pharma IncDyanavel Xr | $576,718 | $6,21415 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,166 psychiatry providers in Michigan.
Other psychiatry in Rochester Hills
- Rose DemczukRochester Hills$10K
- Andreas SidiropoulasDetroit$2.8M
- Welton WashingtonYpsilanti$1.4M
- Manzar RajputMonroe$612K
- William GuySouthfield$562K
- Robert LagrouClarkston$267K
- Michael IngramBay City$255K
- Samuel WedesLivonia$158K
- Arash JavanbakhtDetroit$102K
- Theodore RuzaWest Bloomfield$100K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.